146 results on '"Pellicelli, Adriano M."'
Search Results
2. Sofosbuvir plus daclatasvir for post-transplant recurrent hepatitis C: Potent antiviral activity but no clinical benefit if treatment is given late
3. Long term nucleotide and nucleoside analogs treatment in chronic hepatitis B HBeAg negative genotype D patients and risk for hepatocellular carcinoma
4. Daclatasvir combined with sofosbuvir or simeprevir in liver transplant recipients with severe recurrent hepatitis C infection
5. SAFETY OF SORAFENIB THERAPY IN ELDERLY ADULTS WITH ADVANCED HEPATOCELLULAR CARCINOMA
6. Sustained virological response in patients with HCV treated with daclatasvir plus sofosbuvir, with or without ribavirin: a large, field-practice study
7. Benefit of weight based dosages of Ribavirin (RBV) in combination with PegInterferon (PegIFN) α2a in naïve patients with HCV2 and HCV3: results of an Italian Randomized Controlled Trial, the WRITE study: 1737
8. Impact of liver fibrosis in development of hepatocellular carcinoma in HBeAg negative genotype D patients with chronic hepatitis B treated with nucleos(†)ide analogues: 21
9. Multiclass HCV resistance to direct-acting antiviral failure in real-life patients advocates for tailored second-line therapies
10. Plasma Cytokines and Portopulmonary Hypertension in Patients With Cirrhosis Waiting for Orthotopic Liver Transplantation
11. Treatment of hepatitis C virus carriers with persistently normal alanine aminotransferase levels with peginterferon α-2a and ribavirin: a multicentric study
12. Epicardial Adipose Tissue is Related to Carotid Intima-Media Thickness and Visceral Adiposity in HIV-Infected Patients with Highly Active Antiretroviral Therapy-Associated Metabolic Syndrome
13. Clinical course of cardiomyopathy in HIV-infected patients with or without encephalopathy related to the myocardial expression of tumour necrosis factor-α and nitric oxide synthase
14. Clinical course of cardiomyopathy in HIV-infected patients with or without encephalopathy related to the myocardial expression of tumour necrosis factor-α and nitric oxide synthase
15. The expanding role of the cardiologist in the care of HIV infected patients
16. HIV-Associated Coronary Arteritis in a Patient with Fatal Myocardial Infarction
17. Primary Pulmonary Hypertension in HIV Patients: A Systematic Review
18. Clinical Manifestation of HIV-Related Pulmonary Hypertension
19. Pathogenesis of HIV-Related Pulmonary Hypertension
20. HCV genotype 1a shows a better virological response to antiviral therapy than HCV genotype 1b
21. Clinical course of cardiomyopathy in HIV-infected patients with or without encephalopathy related to the myocardial expression of tumour necrosis factor-α and nitric oxide synthase
22. Lack of reduction in serum alpha‐fetoprotein during treatment with direct antiviral agents predicts hepatocellular carcinoma development in a large cohort of patients with hepatitis C virus‐related cirrhosis
23. Short versus standard treatment with pegylated interferon alfa-2A plus ribavirin in patients with hepatitis C virus genotype 2 or 3: the cleo trial
24. Long-term efficacy of interferon alpha-2b and lamivudine in combination compared to lamivudine monotherapy in patients with chronic hepatitis B. An Italian multicenter, randomized trial
25. Eustachian valve endocarditis: a rare localization of right side endocarditis. A case report and review of the literature
26. Sarcopenia is associated with reduced survival in patients with advanced hepatocellular carcinoma undergoing sorafenib treatment
27. Yttrium-90 Radioembolization for Hepatocellular Carcinoma Prior to Liver Transplantation
28. Cholestatic hepatitis C after chemotherapy containing rituximab in diffuse large B cell lymphoma
29. Reply
30. Liver cirrhosis and rhino-orbital mucormycosis, a possible but rare association: description of a clinical case and literature review
31. Efficacy and safety of sofosbuvir/simeprevir plus flat dose ribavirin in genotype 1 elderly cirrhotic patients: A real-life study.
32. Short versus standard treatment with pegylated interferon alfa-2a plus ribavirin in patients with hepatitis C virus genotype 2 or 3: the CLEO trial
33. Adefovir and lamivudine in combination compared with adefovir monotherapy in HBeAg-negative adults with chronic hepatitis B virus infection and clinical or virologic resistance to lamivudine: A retrospective, multicenter, nonrandomized, open-label study
34. Porphyria cutanea tarda in an HCV-positive liver transplant patient: a case report
35. Which is the real efficacy of pegylated interferon alpha 2a or 2b plus ribavirin in HCV infected patients with advanced fibrosis?
36. Role of ribavirin in hepatitis flare in HCV-infected patients with B cell non Hodgkin's lymphoma treated with rituximab-containing regimens
37. Hepatitis C virus-related B cell subtypes in non Hodgkin's lymphoma
38. Liver cirrhosis and rhino-orbital mucormycosis, a possible but rare association: description of a clinical case and literature review
39. Relation of Subepicardial Adipose Tissue to Carotid Intima-Media Thickness in Patients With Human Immunodeficiency Virus
40. Relation of Epicardial Fat and Alanine Aminotransferase in Subjects With Increased Visceral Fat
41. Contrast Echocardiography of Right Atrial Mass due to Hepatocellular Carcinoma
42. Eustachian valve endocarditis: a rare localization of right side endocarditis. A case report and review of the literature
43. HIV-related pulmonary hypertension
44. Endocarditis Caused byAspergillusSpecies in Injection Drug Users
45. Role of Human Immunodeficiency Virus in Primary Pulmonary Hypertension
46. Short versus standard treatment with pegylated interferon alfa-2A plus ribavirin in patients with hepatitis C virus genotype 2 or 3: the cleo trial.
47. Endocarditis Caused by Aspergillus Species in Injection Drug Users.
48. Benefit of weight based dosages of Ribavirin (RBV) in combination with PegInterferon (PegIFN) alpha 2a in naive patients with HCV2 and HCV3: results of an Italian Randomized Controlled Trial, the WRITE study
49. Virological failures to direct acting antivirals (DAA) regimens in a real life setting show frequent resistance associated variants and may require re-treatment with unconventional strategies
50. Natural NS3, NS5A and NS5B HCV resistance is common in real practice, differently associated to HCV genotypes and response to NS5A inhibitors
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.